New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The role of dopamine agonist treatment and age at motor symptoms onset

Journal of Psychopharmacology

Volumn 21, Issue 5, 2007, Pages 501-506

  Giladi, Nir ^a,b   Weitzman, Nina ^a   Schreiber, Shaul ^a,b   Shabtai, Herzel ^a   Peretz, Chava ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bulimia; Dopamine agonist drugs; Dopamine dysregulation syndrome; Gambling; Hedonic homeostatic dysregulation; Hypersexuality; Hypomania; Impulse control disorder; Parkinson's disease; Shopping

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CLINICAL STUDY; CONTROLLED STUDY; DRIVE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCHIATRY; RISK FACTOR; SEX DIFFERENCE; SEXUAL BEHAVIOR; SHOPPING; TREATMENT DURATION;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; DOPAMINE AGONISTS; FEEDING BEHAVIOR; FEMALE; GAMBLING; HUMANS; IMPULSIVE BEHAVIOR; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SEXUAL BEHAVIOR; TREMOR;

EID: 34547121978     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106073109     Document Type: Article

References (36)

1. Alegret M., Junque C., Valldeoriola F., Vendrell P., Marti M.J., Tolosa E. (2001) Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 70: 394 - 396
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4 th edn. Washington: American Psychiatric Press
3. Bearn J., Evans A., Kelleher M., Turner K., Less A. (2004). Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 76 (3). 305 - 310
4. Berridge K.C., Robinson T.E. (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309 - 369
5. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E., Arai K., Braak H. (2001) Alpha-synuclein immunopositive Parkinson's disease-related inclusion in lower brain stem nuclei. Acta Neuropathol 101: 195 - 201
6. Cummings J.L. (1991) Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 39: 708 - 716
7. Driver-Dinkley E., Samanta J., Stacy M. (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61: 422 - 423
8. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., Brooks D.J., Lees A.J., Piccini P. (2006). Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 (5). 852 - 858
9. Fasano A., Elia A.E., Soleti F., Guidubaldi A., Bentivoglio A.R. (2006) Punding and computer addiction in Parkinson's disease. Mov Disord 24: [Epub ahead of print]
10. Folstein M F., Folstein S E., McHugh P.R. (1975). ' Mini-Mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189 - 198
11. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., Lees A.J. (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68: 423 - 428
12. Glosser G., Clark C., Freundlich B., Kliner-Krenzel L., Flaherty P. (1995) A controlled investigation of current and premorbid personality characteristics of Parkinson's disease patients. Mov Disord 10: 201 - 206.
13. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., Giladi N., Holloway R.G., Moore C.G., Wenning G.K., Yahr M.D., Seidl L., Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19 (9). 1020 - 1028
14. Goodman W.K., McDougle C.J., Lawrence L.P. (1990) Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive- compulsive disorder. J Clin Psychiatry 51: 36 - 43
15. Gschwandtner U., Aston J., Renaud S., Fuhr P. (2001) Pathological gambling in patients with Parkinson's disease. Clin Neuropharmacol 24: 170 - 172
16. Harsch H.H., Miller M., Young L.D. (1985). Induction of mania by L-dopa in nonbipolar patient. J Clin Psychopharmacol 5: 338 - 339
17. Hoehn M.M., Yahr M.D. (1967) Parkinsonism; onset, progression and mortality. Neurology 17: 153 - 163
18. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinical pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181 - 184
19. Jacobs H., Heberlein I., Vieregge A., Vieregge P. (2001) Personality traits in young patients with Parkinson's disease. Acta Neurol Scand 103: 82 - 87
20. Jenike M.A. (2004) Clinical practice. Obsessive-compulsive disorder. N Engl J Med 350: 259 - 265
21. Kim S.E., Choi J.Y., ChoyY.S., Choy Y., Lee W.Y. (2004) Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 45: 923 - 924
22. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., Ahlskog J.E. (2005). Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 (6). 381 - 386
23. Lawrence A.D., Evans A.H., Lees A.J. (2003) Compulsive use of dopamine replacement therapy in Parkinson's disease: reward system gone away? Lancet Neurol 2: 595 - 604
24. Maia A.F., Pinto A.S., Barbosa E.R., Menezes P.R., Miguel E.C. (2003). Obsessive-compulsive symptoms, obsessive-compulsive disorder and related disorders in Parkinson's disease. Neuropsychiatry Clin Neurosci 15: 371 - 374
25. Menza M.A., Forman N.E., Goldstein H.S., Golbe L.I. (1990) Parkinson's disease, personality and dopamine. J Neuropsychiatry Clin Neurosci 2: 282 - 287
26. Molina J.A., Sainz-Artiga M.J., Fraile A., Jimenez-Jimenez F.J., Villanueva C., Orti-Pareja M., Bermejo F. (2000) Pathological gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment ? Mov Disord 15: 869 - 872
27. Nirenberg M.J., Waters C. (2006). Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21 (4). 524 - 529
28. Nocjar C., Panksepp J. (2002) Chronic intermittent amphetamine pretreatment enhances future appetitive behavior for drug- and natural-reward: interaction with environmental variables. Behav Brain Res 128 (2). 189 - 203
29. Pezzella F.R., Colosimo C., Vanacore N., Di Rezze S, Chianese M., Fabbrini G. (2005). Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20: 77 - 81
30. Robinson T.E., Berridge K.C. (2003) Addiction. Annu Rev Psychol 54: 963 - 976
31. Rub U., Del Tredici K., Schultz C., Ghebremedhin E., de Vos R.A., Jansen Steur E., Braak H. (2002) Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 23: 245 - 254
32. Stein D.J. (2002) Obsessive-compulsive disorder. Lancet 360: 397 - 405
33. Todes C.J., Lees A.J. (1985) The pre-morbid personality of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 48: 97 - 100
34. Uitti R.J., Tanner C.M., Rajput A.H., Goetz C.G., Klawans H.L., Thiessen B. (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12: 375 - 383
35. Webster D.D. (1968) Clinical analysis of the disability in Parkinson's disease. Mod Treat 5: 257 - 282
36. Young A.M., Moran P.M., Joseph M.H. (2005). The role of dopamine in conditioning and latent inhibition: what, when, where and how? Neurosci Biobehav Rev 29: 963 - 976